[{"from": "human", "value": "What can you tell me about this molecule? [C][C][=Branch1][C][=O][N][C@@H1][C][C][C][C@@H1][Branch1][Ring2][C][Ring1][=Branch1][C][=Branch1][C][=O][N][C][=N][C][=C][Branch2][Ring1][=Branch2][C][=Branch1][Ring2][=C][Ring1][=Branch1][C][=C][C][C][Branch1][=Branch2][C][N][Ring1][Branch1][N][=C][Ring1][Branch2][Branch1][C][C][C][Cl]"}, {"from": "gpt", "value": "The molecule is a selective, short-acting inhibitor of the serine/threonine cyclin-dependent kinase 9 (CDK9), the catalytic subunit of the RNA polymerase II (RNA Pol II) elongation factor positive transcription elongation factor b (PTEF-b; PTEFb), with potential antineoplastic activity. Upon intravenous administration, AZD4573 binds to and blocks the phosphorylation and kinase activity of CDK9, thereby preventing PTEFb-mediated activation of RNA Pol II, leading to the inhibition of gene transcription of various anti-apoptotic proteins. This induces cell cycle arrest and apoptosis, and leads to a reduction in tumor cell proliferation. CDK9 regulates elongation of transcription through phosphorylation of RNA polymerase II at serine 2 (p-Ser2-RNAPII). It is upregulated in various tumor cell types and plays a key role in the regulation of Pol II-mediated transcription of anti-apoptotic proteins. Tumor cells are dependent on anti-apoptotic proteins for their survival."}]